Join

Compare · HJLI vs WST

HJLI vs WST

Side-by-side comparison of Hancock Jaffe Laboratories, Inc. (HJLI) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HJLI and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • WST is the larger of the two at $22.59B, about 248.6x HJLI ($90.9M).
  • WST has hit the wire 5 times in the past 4 weeks while HJLI has been quiet.
  • WST has more recent analyst coverage (17 ratings vs 0 for HJLI).
MetricHJLIWST
Company
Hancock Jaffe Laboratories, Inc.
West Pharmaceutical Services Inc.
Price
$10.42-1.33%
$320.02+1.78%
Market cap
$90.9M
$22.59B
1M return
-
-
1Y return
-
-
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
2018
News (4w)
0
5
Recent ratings
0
17
HJLI

Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

WST

West Pharmaceutical Services Inc.

West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Latest HJLI

Latest WST